Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 6/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23802375 | 0.88 | FDPS (0.40) | OPRD1OPRK1NAMPTGPR119POLB | |
| SCHEMBL4978208 | 0.82 | FDPS (0.38) | — | |
| SCHEMBL3257474 | 0.80 | OPRD1 (0.52) | OPRD1OPRK1NAMPTGPR119POLB | |
| SCHEMBL23802498 | 0.80 | OPRD1 (0.38) | OPRD1OPRK1NAMPTGPR119POLB | |
| SCHEMBL2731871 | 0.79 | GPR119 (0.45) | OPRD1OPRK1GPR119POLBACHE | |
| SCHEMBL1088021 | 0.79 | CYP46A1 (0.54) | OPRD1OPRK1GPR119POLB | |
| SCHEMBL23802374 | 0.79 | OPRD1 (0.37) | OPRD1OPRK1NAMPTGPR119POLB | |
| SCHEMBL30585014 | 0.79 | CYP46A1 (0.54) | OPRD1OPRK1GPR119POLB | |
| SCHEMBL25133817 | 0.77 | GPR119 (0.53) | OPRD1OPRK1NAMPTGPR119 | |
| SCHEMBL3258235 | 0.76 | OPRD1 (0.50) | OPRD1OPRK1NAMPTGPR119POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | TUCKER HOWARD | 2008-01-24 | — | — | US | disclosed |
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | TUCKER HOWARD | 2008-01-24 | — | — | US | disclosed |
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | TUCKER HOWARD | 2008-01-24 | — | — | US | disclosed |
| EP-1761491-A1 | NOVEL PIPERIDINE/8-AZABICYCLO [3.2.1] OCTAN DERIVATIVES AS MODUILATORS OF CHEMOKINE RECEPTOR CCR5 | AstraZeneca AB (SE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006001752-A1 | NOVEL PIPERIDINE/8-AZABICYCLO [3.2.1] OCTAN DERIVATIVES AS MODUILATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | CCR5, CXCR1, CCR2 | OPRD1 30/4885OPRK1 51/4885NAMPT 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.